文献速递妇科肿瘤

非上皮性卵巢肿瘤:1989-2015年荷兰发病率与生存趋势

Overview of non-epithelial ovarian tumours: Incidence and survival in the Netherlands, 1989-2015.
PubMed 文献 · Eur J Cancer · 2019-07-18

该研究基于荷兰癌症登记处1989-2015年数据,纳入1258例非上皮性卵巢恶性肿瘤(生殖细胞肿瘤752例、性索间质肿瘤341例、肉瘤165例),分析发病率、治疗和总生存。生殖细胞肿瘤和性索间质肿瘤发病率低且稳定,预后良好;卵巢原发肉瘤极罕见且预后差。

要点

  • 非上皮性卵巢肿瘤占卵巢肿瘤约5%,以生殖细胞肿瘤最常见(60%)。
  • 生殖细胞肿瘤和性索间质肿瘤预后良好,五年总生存分别升至88%和81%。
  • 卵巢原发肉瘤极罕见,五年总生存仅29%,预后仍差。

核心结论

  • 恶性生殖细胞肿瘤和性索间质肿瘤罕见,近几十年发病率无显著变化,预后良好且略有改善。
  • 卵巢原发肉瘤极罕见,预后仍差。

研究设计与样本

  • 基于荷兰癌症登记处的全国 population-based 研究,纳入1989-2015年诊断的非上皮性卵巢恶性肿瘤女性。
  • 共纳入1258例非上皮性卵巢肿瘤,包括752例生殖细胞肿瘤、341例性索间质肿瘤和165例肉瘤。

主要发现

  • 生殖细胞肿瘤的欧洲年龄标化发病率为0.4/10万人/年,性索间质肿瘤为0.2,肉瘤为0.1。
  • 约97%患者接受原发肿瘤手术切除,31%接受全身治疗,3%接受放疗。
  • 生殖细胞肿瘤五年总生存从73%升至88%(p = 0.03),性索间质肿瘤从64%升至81%(p = 0.57),肉瘤从20%升至29%(p = 0.14)。

临床怎么用

  • 临床应认识到非上皮性卵巢肿瘤以生殖细胞肿瘤最常见,手术是主要初始治疗。
  • 生殖细胞肿瘤和性索间质肿瘤预后较好,但卵巢原发肉瘤预后差,需重视。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: About 5% of ovarian tumours have a non-epithelial histology, including germ cell tumours (GCTs), sex cord-stromal tumours (SCSTs) and sarcomas. Because these non-epithelial ovarian tumours are rare and population-based studies are scarce, the aim of this population-based study is to describe trends in the incidence, treatment and survival of women with these tumours in the Netherlands. METHODS: All women diagnosed with non-epithelial ovarian malignant tumours in the Netherlands between 1989 and 2015 were identified from the Netherlands Cancer Registry. Data on demographics, tumour characteristics and initial treatment were collected, and overall survival was analysed. RESULTS: A total of 1258 non-epithelial ovarian tumours were identified comprising 752 GCTs (60%), 341 SCSTs (27%) and 165 sarcomas (13%). The European age-standardised incidence rate (ESR) was 0.4 per 100,000 persons per year for GCTs, 0.2 for SCSTs and 0.1 for sarcomas. Approximately 97% of patients underwent surgical resection for the primary tumour, 31% received systemic treatment and 3% radiotherapy. Between the late 1980s and 2015, five-year overall survival improved for all histologic subtypes: GCTs rose from 73% to 88% (p = 0.03), SCSTs from 64% to 81% (p = 0.57) and sarcomas from 20% to 29% (p = 0.14). CONCLUSION: Malignant GCTs and SCSTs are rare, and their incidence has not significantly changed over recent decades. They have a good prognosis, which also improved slightly during this period. Primary sarcomas of the ovary are extremely rare and still have a poor prognosis.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. van der Hel OL, Timmermans M, van Altena AM, et al. Overview of non-epithelial ovarian tumours: Incidence and survival in the Netherlands, 1989-2015. Eur J Cancer. 2019. PMID: 31326731. doi:10.1016/j.ejca.2019.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。